USE OF INHALED TOBRAMYCIN IN PATIENTS WITH CYSTIC FIBROSIS

The results of a few studies evaluating the efficacy and safety of nebulized tobramycin solution used in patients with cystic fibrosis have been published to date. Pulmonary deposition of inhaled tobramycin and its lung produced concentrations are rather high (10-25 times greater than the minimum suppressing concentration) and systemic absorption is extremely low. The treatment makes it possible to improve external respiratory function, to lower the colonization of the bronchi with Pseudomonas aeruginosa, and, in many cases, to achieve its eradication. Inhaled tobramycin reduces the sputum level of inflammatory cytokines in patients with cystic fibrosis, which slows down irreversible lung changes. Inhaled antibacterial therapy results in a reduction in the number of exacerbations, the frequency of admissions, and the need for systemic antibiotics.